Delusional parasitosis associated with dialysis treated with aripiprazole.
DOI:
https://doi.org/10.20344/amp.457Abstract
We report the case of a 75-year-old Chinese lady that presented delusional parasitosis with visual hallucinations four months after starting peritoneal dialysis. This psychosis is characterized by the persistent and unshakable belief of being infested with small living organisms, although there is no medical evidence for this. The patient had no previous history of psychiatric disorders, presented diminished visual acuity due to cataracts and macular degeneration, did not show cognitive deterioration, and was medicated with erythropoietin. During the course of the psychosis she presented an episode of visual hallucinations possibly related to Charles Bonnet syndrome. After two months of treatment with aripiprazole the psychotic symptoms remitted considerably. Aripiprazole is a neuroleptic to consider in the treatment of delusional parasitosis.Downloads
Downloads
How to Cite
Issue
Section
License
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.